All News SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-17 am EDT			5-day change	1st Jan Change
159 ^JPY	+1.92%		-3.64%	-35.63%

Apr. 19	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI
Mar. 18	SymBio Pharmaceuticals Limited amended terms of the transaction	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	Apr. 18	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	Mar. 17	CI
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	Feb. 12	MT
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	Feb. 08	CI
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	Feb. 08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	Nov. 15	MT
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	Nov. 14	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 14	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	Nov. 09	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	23-10-05	CI
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-04-27	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	23-04-25	MT
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	23-04-23	CI
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	23-03-22	CI
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	23-03-16	AQ
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

All News

Filters